Advertisement

FasL and Fas

Typical Members of the TNF Ligand and Receptor Family
  • Anja Krippner-Heidenreich
  • Peter Scheurich
Chapter
  • 272 Downloads
Part of the Medical Intelligence Unit book series (MIUN)

Abstract

The membrane receptor Fas is one of the central members of the TNF receptor superfamily, representing the prototype of an apoptosis inducer. Its cognate ligand, FasL, is expressed as a type II transmembrane protein, but also exists as a soluble molecule. As typical for all members of the TNF receptor superfamily, Fas signaling is induced by multimerization. Both molecules share structural features with their respective family members. Hallmarks of Fas are two and a half copies of a cysteine rich domain in the extracellular part, required for ligand binding and self-association and the intracellular death domain, essential for apoptosis induction. Characteristics of the FasL are the stable formation of homotrimers, each protomer consisting of two β-sheets in a typical “jelly roll” arrangement and a proline-rich domain involved in intracellular transport and reverse signaling.

Keywords

Tumor Necrosis Factor Receptor Death Domain Tumor Necrosis Factor Receptor Superfamily Soluble FasL Human FasL 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745–756.PubMedCrossRefGoogle Scholar
  2. 2.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  3. 3.
    Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes Dev 1998; 12:2821–2830.PubMedGoogle Scholar
  4. 4.
    Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675–680.PubMedCrossRefGoogle Scholar
  5. 5.
    Lockshin RA, Osborne B, Zakeri Z. Cell death in the third millennium. Cell Death Differ 2000; 7:2–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239–257.PubMedGoogle Scholar
  7. 7.
    Nagata S. Apoptosis by death factor. Cell 1997; 88:355–365.PubMedCrossRefGoogle Scholar
  8. 8.
    Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301–305.PubMedCrossRefGoogle Scholar
  9. 9.
    Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747–1756.PubMedCrossRefGoogle Scholar
  10. 10.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806–809.PubMedCrossRefGoogle Scholar
  11. 11.
    Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233–243.PubMedCrossRefGoogle Scholar
  12. 12.
    Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169–1178.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheng J, Liu C, Koopman WJ et al. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995; 154:1239–1245.PubMedGoogle Scholar
  14. 14.
    Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998; 23:74–79.PubMedCrossRefGoogle Scholar
  15. 15.
    Marsters SA, Frutkin AD, Simpson NJ et al. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem 1992; 267:5747–5750.PubMedGoogle Scholar
  16. 16.
    Yan H, Chao MV. Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding. J Biol Chem 1991; 266:12099–12104.PubMedGoogle Scholar
  17. 17.
    Orlinick JR, Vaishnaw A, Elkon KB et al. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 1997; 272:28889–28894.PubMedCrossRefGoogle Scholar
  18. 18.
    Starling GC, Bajorath J, Emswiler J et al. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997; 185:1487–1492.PubMedCrossRefGoogle Scholar
  19. 19.
    Banner DW, D’Arcy A, Janes W et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73:431–445.PubMedCrossRefGoogle Scholar
  20. 20.
    Papoff G, Cascino I, Eramo A et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156:4622–4630.PubMedGoogle Scholar
  21. 21.
    Papoff G, Hausler P, Eramo A et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999; 274:38241–38250.PubMedCrossRefGoogle Scholar
  22. 22.
    Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351–2354.PubMedCrossRefGoogle Scholar
  23. 23.
    Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288:2354–2357.PubMedCrossRefGoogle Scholar
  24. 24.
    Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268:10932–10937.PubMedGoogle Scholar
  25. 25.
    Tartaglia LA, Ayres TM, Wong GH et al. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74:845–853.PubMedCrossRefGoogle Scholar
  26. 26.
    Wajant H. Death receptors. Essays Biochem 2003; 39:53–71.PubMedGoogle Scholar
  27. 27.
    Pan G, Bauer JH, Haridas V et al. Identification and functional characterization of DR6, a novel death domain-containing. TNF receptor FEBS Lett 1998; 431:351–356.CrossRefGoogle Scholar
  28. 28.
    Koppinen P, Pispa J, Laurikkala J et al. Signaling and subcellular localization of the TNF receptor Edar. Exp Cell Res 2001; 269:180–192.PubMedCrossRefGoogle Scholar
  29. 29.
    Huang B, Eberstadt M, Olejniczak ET et al. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384:638–641.PubMedCrossRefGoogle Scholar
  30. 30.
    Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103:273–282.PubMedCrossRefGoogle Scholar
  31. 31.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314–317.PubMedCrossRefGoogle Scholar
  32. 32.
    Matsuzawa A, Moriyama T, Kaneko T et al. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J Exp Med 1990; 171:519–531.PubMedCrossRefGoogle Scholar
  33. 33.
    Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11:294–300.PubMedCrossRefGoogle Scholar
  34. 34.
    Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16:39–43.PubMedCrossRefGoogle Scholar
  35. 35.
    Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003; 10:124–133.PubMedCrossRefGoogle Scholar
  36. 36.
    Lahm A, Paradisi A, Green DR et al. Death fold domain interaction in apoptosis. Cell Death Differ 2003; 10:10–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Stahnke K, Hecker S, Kohne E et al. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol 1998; 26:844–850.PubMedGoogle Scholar
  38. 38.
    Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759–1762.PubMedCrossRefGoogle Scholar
  39. 39.
    Cascino I, Fiucci G, Papoff G et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154:2706–2713.PubMedGoogle Scholar
  40. 40.
    Ruberti G, Cascino I, Papoff G et al. Fas splicing variants and their effect on apoptosis. Adv Exp Med Biol 1996; 406:125–134.PubMedGoogle Scholar
  41. 41.
    Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969–976.PubMedCrossRefGoogle Scholar
  42. 42.
    Orlinick JR, Elkon KB, Chao MV. Separate domains of the human fas ligand dictate self-association and receptor binding. J Biol Chem 1997; 272:32221–32229.PubMedCrossRefGoogle Scholar
  43. 43.
    Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989; 264:17595–17605.PubMedGoogle Scholar
  44. 44.
    Eck MJ, Beutler B, Kuo G et al. Crystallization of trimeric recombinant human tumor necrosis factor (cachectin). J Biol Chem 1988; 263:12816–12819.PubMedGoogle Scholar
  45. 45.
    Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature 1989; 338:225–228.PubMedCrossRefGoogle Scholar
  46. 46.
    Eck MJ, Ultsch M, Rinderknecht E et al. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem 1992; 267:2119–2122.PubMedGoogle Scholar
  47. 47.
    Tanaka M, Itai T, Adachi M et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4:31–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Suda T, Hashimoto H, Tanaka M et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186:2045–2050.PubMedCrossRefGoogle Scholar
  49. 49.
    Adachi M, Suematsu S, Suda T et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996; 93:2131–2136.PubMedCrossRefGoogle Scholar
  50. 50.
    Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777–1783.PubMedCrossRefGoogle Scholar
  51. 51.
    Mariani SM, Matiba B, Baumler C et al. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995; 25:2303–2307.PubMedCrossRefGoogle Scholar
  52. 52.
    Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729–733.PubMedCrossRefGoogle Scholar
  53. 53.
    Moss ML, Jin SL, Milla ME et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733–736.PubMedCrossRefGoogle Scholar
  54. 54.
    Matsuno H, Yudoh K, Watanabe Y et al. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001; 28:22–28.PubMedGoogle Scholar
  55. 55.
    Powell WC, Fingleton B, Wilson CL et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999; 9:1441–1447.PubMedCrossRefGoogle Scholar
  56. 56.
    Vargo-Gogola T, Crawford HC, Fingleton B et al. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002; 408:155–161.PubMedCrossRefGoogle Scholar
  57. 57.
    Wenzel J, Sanzenbacher R, Ghadimi M et al. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor. FEBS Lett 2001; 509:255–262.PubMedCrossRefGoogle Scholar
  58. 58.
    Blott EJ, Bossi G, Clark R et al. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci 2001; 114:2405–2416.PubMedGoogle Scholar
  59. 59.
    Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179:873–879.PubMedCrossRefGoogle Scholar
  60. 60.
    Tanaka M, Suda T, Takahashi T et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995; 14:1129–1135.PubMedGoogle Scholar
  61. 61.
    Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187:1205–1213.PubMedCrossRefGoogle Scholar
  62. 62.
    Shudo K, Kinoshita K, Imamura R et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31:2504–2511.PubMedCrossRefGoogle Scholar
  63. 63.
    Aoki K, Kurooka M, Chen JJ et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001; 2:333–337.PubMedCrossRefGoogle Scholar
  64. 64.
    Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793–802.PubMedCrossRefGoogle Scholar
  65. 65.
    LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66–75.PubMedCrossRefGoogle Scholar
  66. 66.
    Muhlenbeck F, Schneider P, Bodmer JL et al. TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000.Google Scholar
  67. 67.
    Haswell LE, Glennie MJAl, Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001; 31:3094–3100.PubMedCrossRefGoogle Scholar
  68. 68.
    Wajant H, Moosmayer D, Wuest T et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101–4106.PubMedCrossRefGoogle Scholar
  69. 69.
    Ottonello L, Tortolina G, Amelotti M et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162:3601–3606.PubMedGoogle Scholar
  70. 70.
    Seino K, Iwabuchi K, Kayagaki N et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161:4484–4488.PubMedGoogle Scholar
  71. 71.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76:959–962.PubMedCrossRefGoogle Scholar
  72. 72.
    D’Arcy A, Banner DW, Janes W et al. Crystallization and preliminary crystallographic analysis of a TNF-beta-55 kDa TNF receptor complex. J Mol Biol 1993; 229:555–557.PubMedCrossRefGoogle Scholar
  73. 73.
    Weber CH, Vincenz C. A clocking model of key components of the DISC complex: death domain superfamily interactions redefined. FEBS Lett 2001; 492:171–176.PubMedCrossRefGoogle Scholar
  74. 74.
    Kull FC Jr., Jacobs S, Cuatrecasas P. Cellular receptor for 1251-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci USA 1985; 82:5756–5760.PubMedCrossRefGoogle Scholar
  75. 75.
    Scheurich P, Ucer U, Kronke M et al. Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer 1986; 38:127–133.PubMedCrossRefGoogle Scholar
  76. 76.
    Algeciras-Schimnich A, Shen L, Barnhart BC et al. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002; 22:207–220.PubMedCrossRefGoogle Scholar
  77. 77.
    Krippner-Heidenreich A, Tubing F, Bryde S et al. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 2002; 277:44155–44163.PubMedCrossRefGoogle Scholar
  78. 78.
    Cremesti A, Paris F, Grassme H et al. Ceramide enables fas to cap and kill. J Biol Chem 2001; 276:23954–23961.PubMedCrossRefGoogle Scholar
  79. 79.
    Grassme H, Cremesti A, Kolesnick R et al. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003; 22:5457–5470.PubMedCrossRefGoogle Scholar
  80. 80.
    Schutze S, Machleidt T, Adam D et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 1999; 274:10203–10212.PubMedCrossRefGoogle Scholar
  81. 81.
    Holler N, Tardivel A, Kovacsovics-Bankowski M et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003; 23:1428–1440.PubMedCrossRefGoogle Scholar
  82. 82.
    Grell M, Wajant H, Zimmermann G et al. The type 1 receptor (CD 120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998; 95:570–575.PubMedCrossRefGoogle Scholar
  83. 83.
    Hueber AO, Bernard AM, Herincs Z et al. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep 2002; 3:190–196.PubMedCrossRefGoogle Scholar
  84. 84.
    Rehemtulla A, Hamilton CA, Chinnaiyan AM et al. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem 1997; 272:25783–25786.PubMedCrossRefGoogle Scholar
  85. 85.
    Friesen C, Herr I, Krammer PH et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574–577.PubMedCrossRefGoogle Scholar
  86. 86.
    Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001; 7:95–106.PubMedCrossRefGoogle Scholar
  87. 87.
    Holler N, Zaru R, Micheau O et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1:489–495.PubMedCrossRefGoogle Scholar
  88. 88.
    Sato T, Irie S, Kitada S et al. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268:411–415.PubMedCrossRefGoogle Scholar
  89. 89.
    Yanagisawa J, Takahashi M, Kanki H et al. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997; 272:8539–8545.PubMedCrossRefGoogle Scholar
  90. 90.
    Ungefroren H, Kruse ML, Trauzold A et al. FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001; 114:2735–2746.PubMedGoogle Scholar
  91. 91.
    Chu K, Niu X, Williams LT. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci USA 1995; 92:11894–11898.PubMedCrossRefGoogle Scholar
  92. 92.
    Vassilev A, Ozer Z, Navara C et al. Bruton’s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999; 274:1646–1656.PubMedCrossRefGoogle Scholar
  93. 93.
    Wang X, DeFrances MC, Dai Y et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor. Met Mol Cell 2002; 9:411–421.CrossRefGoogle Scholar
  94. 94.
    Yu KY, Kwon B, Ni J et al. A newly identified member of tumor necrosis factor receptor super-family (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274:13733–13736.PubMedCrossRefGoogle Scholar
  95. 95.
    Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699–703.PubMedCrossRefGoogle Scholar
  96. 96.
    Migone TS, Zhang J, Luo X et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16:479–492.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2006

Authors and Affiliations

  • Anja Krippner-Heidenreich
    • 1
  • Peter Scheurich
    • 1
  1. 1.Institute of Cell Biology and ImmunologyUniversity of StuttgartStuttgartGermany

Personalised recommendations